News & Events
-
September 30, 2019
The Critical Path for Parkinson’s Consortium (CPP) welcomes PMD Alliance as newest member
The Critical Path for Parkinson’s Consortium (CPP) is thrilled to welcome the PMD Alliance (Parkinson & Movement Disorder Alliance) as our newest member. The PMD Alliance is an independent, national nonprofit organization that provides opportunities for people impacted by Parkinson’s and other movement disorders to learn, live life more fully, and connect with others. Their...... -
August 12, 2019
C-Path’s Critical Path for Parkinson’s Consortium (CPP) is pleased to welcome Linda L. Restifo, MD, PhD, as a Visiting Scientist
C-Path’s Critical Path for Parkinson’s Consortium (CPP) is pleased to welcome Linda L. Restifo, MD, PhD, as a Visiting Scientist. Currently a Professor of Neurology at the University of Arizona College of Medicine – Tucson, Dr. Restifo is a neurogeneticist with broad interests in translational medicine. She will be using her expertise to help CPP...... -
June 19, 2019
The Critical Path for Parkinson’s consortium announces C-Path’s Data Sharing Pioneer Award recipients
The Critical Path for Parkinson’s consortium (CPP) is pleased to announce the following recipients as the first to receive C-Path’s Data Sharing Pioneer Award. This award is bestowed to member organizations and advisors who have demonstrated dedicated commitment to sharing patient-level data for inclusion in our integrated Parkinson’s database. The database is fundamental to CPP’s...... -
July 26, 2018
First-ever biomarker qualified for Parkinson’s is a vital step toward improved clinical trials
FOR IMMEDIATE RELEASE Contact: Kissy Black 615.298.1144 kissyblack@lotosnile.com Tucson, AZ — July 26, 2018 – The Critical Path Institute’s (C-Path) Critical Path for Parkinson’s Consortium (CPP), in partnership with Parkinson’s UK, announces that the European Medicines Agency (EMA) has issued a positive qualification opinion on an imaging test (biomarker) as a tool to enrich...... - May 18, 2018